Search

Your search keyword '"MESH: Peritoneal Neoplasms"' showing total 15 results
Start Over Descriptor "MESH: Peritoneal Neoplasms" Topic 030220 oncology & carcinogenesis
15 results on '"MESH: Peritoneal Neoplasms"'

1. Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients

Author

François Quenet, Christine Chevreau, J.-Y. Blay, Matthieu Faron, G. Ferron, Daniel Orbach, A. Le Cesne, E Nassif, S. Carrere, Antoine Italiano, François Bertucci, Jean-Baptiste Delhorme, Olivier Mir, Marc Pocard, Emmanuelle Bompas, Charles Honoré, Olivier Glehen, AIRPARIF - Surveillance de la qualité de l'air en Île-de-France, Department of Surgical Oncology Institut Claudius Regaud, Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Institut Bergonié [Bordeaux], UNICANCER, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Carcinose Angiogenèse et Recherche Translationnelle, Angiogenese et recherche translationnelle (CART U965), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Claudius Regaud, Institut Gustave Roussy (IGR), Sarcome, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU)

Subjects
Male, 0301 basic medicine, MESH: Combined Modality Therapy, Desmoplastic small-round-cell tumor, Survival, medicine.medical_treatment, [SDV]Life Sciences [q-bio], 0302 clinical medicine, MESH: Child, MESH: Peritoneal Neoplasms, Child, Peritoneal Neoplasms, MESH: Middle Aged, Systemic chemotherapy, Female sex, Cytoreduction Surgical Procedures, MESH: Follow-Up Studies, Middle Aged, Prognosis, Combined Modality Therapy, 3. Good health, Survival Rate, Oncology, MESH: Young Adult, Child, Preschool, 030220 oncology & carcinogenesis, Female, Hyperthermic intraperitoneal chemotherapy, Cure, Adult, medicine.medical_specialty, Poor prognosis, Adolescent, MESH: Survival Rate, education, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, MESH: Prognosis, Young Adult, 03 medical and health sciences, medicine, Overall survival, Humans, Chemotherapy, MESH: Cytoreduction Surgical Procedures, MESH: Patient Selection, MESH: Hyperthermia, Induced, Retrospective Studies, MESH: Adolescent, MESH: Humans, business.industry, Patient Selection, MESH: Child, Preschool, MESH: Adult, MESH: Retrospective Studies, Hyperthermia, Induced, medicine.disease, MESH: Desmoplastic Small Round Cell Tumor, MESH: Male, Surgery, 030104 developmental biology, Chemotherapy, Cancer, Regional Perfusion, Conventional PCI, Desmoplastic small round cell tumor, MESH: Chemotherapy, Cancer, Regional Perfusion, business, MESH: Female, Follow-Up Studies
Abstract

Despite being associated with a very poor prognosis, long-term survivors across all series of Desmoplastic Small Round Cell Tumor (DSRCT) have been reported.To analyze patients 'characteristics associated with a prolonged survival after DSRCT diagnosis.All consecutive patients treated for DSRCT in nine French expert centers between 1991 and 2018 were retrospectively analyzed. Patients with a follow-up of less than 2 years were excluded and cure defined as being disease-free at least 5 years.100 pts were identified (median age 25 years, 89% male). 27 had distant metastases at diagnosis and 80 pts underwent upfront chemotherapy (CT). 71 pts were operated, 20 pts without prior CT). Surgery was macroscopically complete (CC0/1) in 50 pts. Hyperthermic intraperitoneal Chemotherapy (HIPEC) was administered during surgery in 15 pts 54 pts had postoperative CT and 26 pts had postoperative whole abdomino-pelvic RT (WAP-RT). After a median follow-up of 103 months (range 23-311), the median overall survival (OS) was 25 months. The 1- year, 3-year and 5-year OS rates were 90%, 35% and 4% respectively. 5 patients were considered cured after a median disease-free interval of 100 months (range 22-139). Predictive factors of cure were female sex (HR = 0.49, p = 0.014), median PCI12 (HR = 0.32, p = 0.0004), MD Anderson stage I (HR = 0.25, p 0.0001), CC0/1 (HR = 0.34, p 0.0001), and WAP-RT (HR = 0.36, p = 0.00013). HIPEC did not statistically improve survival.Cure in DSRCT is possible in 5% of patients and is best achieved combining systemic chemotherapy, complete cytoreductive surgery and WAP-RT. Despite aggressive treatment, recurrence is common and targeted therapies are urgently needed.

Published
2019
Full Text
View/download PDF

2. Colorectal peritoneal carcinomatosis: What is the future of HIPEC?

Author

François Quenet, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), and CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)

Subjects
MESH: Carcinoma, medicine.medical_specialty, MEDLINE, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, 0302 clinical medicine, Cytoreduction Surgical Procedures, Surveys and Questionnaires, medicine, Carcinoma, Humans, MESH: Peritoneal Neoplasms, MESH: Cytoreduction Surgical Procedures, MESH: Surveys and Questionnaires, Peritoneal Neoplasms, ComputingMilieux_MISCELLANEOUS, MESH: Hyperthermia, Induced, Internet, MESH: Humans, business.industry, General surgery, General Medicine, Hyperthermia, Induced, medicine.disease, Peritoneal carcinomatosis, MESH: Internet, Oncology, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Surgery, business, Colorectal Neoplasms, MESH: Colorectal Neoplasms, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience

Published
2018
Full Text
View/download PDF

3. Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE

Author

Mercier, Frederic, Bakrin, Naoual, Bartlett, David, Goere, Diane, Quenet, François, Dumont, Frédéric, Heyd, Bruno, Abboud, Karine, Marolho, Christelle, Villeneuve, Laurent, Glehen, Olivier, working groups, PSOGI and BIG RENAPE, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Ciblage thérapeutique en Oncologie (EA3738), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, University of Pittsburgh School of Medicine, Pennsylvania Commonwealth System of Higher Education (PCSHE), Département de chirurgie viscérale [Gustave Roussy], Institut Gustave Roussy (IGR), Département de chirurgie, CRLCC Val d'Aurelle - Paul Lamarque, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and CHU Saint-Etienne

Subjects
MESH: Lymphatic Metastasis, Gastroenterology, Peritoneal Neoplasm, Ovarian tumor, 0302 clinical medicine, MESH: Aged, 80 and over, Surgical oncology, Pseudomyxoma peritonei, MESH: Peritoneal Neoplasms, Peritoneal Neoplasms, Granulosa Cell Tumor, MESH: Treatment Outcome, Aged, 80 and over, Ovarian Neoplasms, MESH: Aged, 030219 obstetrics & reproductive medicine, MESH: Middle Aged, Teratoma, MESH: Teratoma, Cytoreduction Surgical Procedures, MESH: Follow-Up Studies, Middle Aged, Neoplasms, Germ Cell and Embryonal, 3. Good health, Survival Rate, MESH: Ovarian Neoplasms, Treatment Outcome, Oncology, MESH: Young Adult, 030220 oncology & carcinogenesis, Lymphatic Metastasis, MESH: Neoplasms, Germ Cell and Embryonal, Hyperthermic intraperitoneal chemotherapy, Female, Carcinoma, Endometrioid, Adult, MESH: Rare Diseases, medicine.medical_specialty, Adolescent, MESH: Survival Rate, [SDV.CAN]Life Sciences [q-bio]/Cancer, Disease-Free Survival, 03 medical and health sciences, Young Adult, Rare Diseases, Internal medicine, medicine, Humans, MESH: Cytoreduction Surgical Procedures, Survival rate, MESH: Hyperthermia, Induced, Aged, Retrospective Studies, MESH: Adolescent, MESH: Humans, MESH: Granulosa Cell Tumor, business.industry, Cancer, MESH: Adult, MESH: Retrospective Studies, Hyperthermia, Induced, MESH: Neoplasms, Cystic, Mucinous, and Serous, medicine.disease, MESH: Carcinoma, Endometrioid, MESH: Disease-Free Survival, Surgery, business, Ovarian cancer, Neoplasms, Cystic, Mucinous, and Serous, MESH: Female, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Follow-Up Studies
Abstract

International audience; PURPOSE:Ovarian cancer is the most common deadly cancer of gynecologic origin. Patients often are diagnosed at advanced stage with peritoneal metastasis. There are many rare histologies of ovarian cancer; some have outcomes worse than serous ovarian cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can be considered for patients with recurrence. This study was designed to assess the impact of CRS and HIPEC on survival of patient with peritoneal metastasis from rare ovarian malignancy.METHODS:A prospective, multicentric, international database was retrospectively searched to identify all patients with rare ovarian tumor (mucinous, clear cells, endometrioid, small cell hypercalcemic, and other) and peritoneal metastasis who underwent CRS and HIPEC through the Peritoneal Surface Oncology Group International (PSOGI) and BIG-RENAPE working group. The postoperative complications, long-term results, and principal prognostic factors were analyzed.RESULTS:The analysis included 210 patients with a median follow-up of 43.5 months. Median overall survival (OS) was 69.3 months, and the 5-year OS was 57.7%. For mucinous tumors, median OS and DFS were not reached at 5 years. For granulosa tumors, median overall survival was not reached at 5 years, and median DFS was 34.6 months. Teratoma or germinal tumor showed median overall survival and DFS that were not reached at 5 years. Differences in OS were not statistically significant between histologies (p = 0.383), whereas differences in DFS were (p

Published
2018
Full Text
View/download PDF

4. Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study

Author

Vadim Gushchin, M. Teo, Frédéric Dumont, David L. Morris, Jean-Jacques Tuech, Guillaume Passot, Lilian Schwarz, R. Kianmanesh, J. Abba, M. De Simone, Antonio Sommariva, D. Kecmanovic, Jan Franko, D. Delroeux, Rami Younan, S.S. Zaveri, Catherine Arvieux, G. Ferron, Olivier Glehen, Mao-Chih Hsieh, Marc Pocard, Frédéric Marchal, P.K. Pande, Gérard Lorimier, Beate Rau, M.-C. Hsieh, Cécile Brigand, F. Rajan, Seung Hyuk Baik, S. Carrère, P. Meeus, F. Guyon, N. Pirro, Y. Liu, P. Ortega-Deballon, Edward A. Levine, P. Piso, Dario Baratti, F. Zinzindohoue, E. Thibaudeau, A. Sardi, Diane Goéré, J.-M. Bereder, A.A.K. Tentes, R. Lo Dico, Mohammad Alyami, J. Porcheron, O. Sgarbura, S. Mehta, L. Gonzalez-Bayon, Aditi Bhatt, M.P. Holtzman, Pascale Mariani, Wim Ceelen, S.A. Ahrendt, K. Abboud, O. Facy, E. Orsenigo, David L. Bartlett, Paul H. Sugarbaker, P. Cachin, N. Bakrin, Laurent Villeneuve, R.P. Edwards, B. Paquette, J.F. Pingpank, P. Rat, K. Lehmann, Y. Yonemura, S. O'Dwyer, P. Peyrat, John Spiliotis, D. Bouzard, Sanket Mehta, K.W. Lee, I. H. J. T. de Hingh, François Quenet, L. Sideris, S. Msika, Roman Yarema, Eduardo Hiroshi Akaishi, Clarisse Eveno, H.J. Zeh, Pierre Dubé, Eun Jung Park, Vahan Kepenekian, Département de chirurgie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Institut Gustave Roussy (IGR), Département de chirurgie, CRLCC Val d'Aurelle - Paul Lamarque, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Ciblage thérapeutique en Oncologie (EA3738), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), and Hospices Civils de Lyon (HCL)

Subjects
Male, MESH: Combined Modality Therapy, Colorectal cancer, Hepatocellular carcinoma, 0302 clinical medicine, MESH: Liver Neoplasms, Pseudomyxoma peritonei, MESH: Peritoneal Neoplasms, Cytoreductive surgery, MESH: Carcinoma, Hepatocellular, Peritoneal Neoplasms, MESH: Treatment Outcome, MESH: Aged, Univariate analysis, MESH: Middle Aged, Standard treatment, Liver Neoplasms, General Medicine, Cytoreduction Surgical Procedures, Middle Aged, Prognosis, Combined Modality Therapy, 3. Good health, Survival Rate, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Hyperthermic intraperitoneal chemotherapy, Female, Adult, medicine.medical_specialty, Carcinoma, Hepatocellular, MESH: Survival Rate, Adolescent, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, 03 medical and health sciences, medicine, Humans, MESH: Cytoreduction Surgical Procedures, MESH: Hyperthermia, Induced, Aged, Retrospective Studies, MESH: Adolescent, MESH: Humans, HIPEC, business.industry, MESH: Adult, MESH: Retrospective Studies, Hyperthermia, Induced, medicine.disease, MESH: Male, Surgery, Peritoneal Cancer Index, Ovarian cancer, business, MESH: Female, Peritoneal carcinomatosis, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Introduction Peritoneal metastasis (PM) of hepatocellular carcinoma (HCC) without distant spread are rare. The related prognosis is poor without standard treatment available. The role of cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is poorly documented. Methods An international multicentric cohort was constituted by retrospective analysis of 21 patients undergoing CRS/HIPEC for PM of HCC between 1992 and 2016 from 10 reference centers of PSOGI. Data on clinical features, treatment strategies, and survival outcomes were analyzed. Results The median time interval from the diagnosis of PM to the procedure was 4.5 months. The median peritoneal cancer index was 14. Sixteen patients had complete cytoreduction (CCR0-1). Ten patients had grades 3 to 4 complications. The median duration of follow-up was 52.2 months. The median OS was 46.7 months. The projected 3y-OS and 5y-OS were 88.9 and 49.4% respectively. The median OS for patients with CCR0-1 resection was not reached whereas it was 5.9 months for those with CCR2-3 resection after CRS (p = 0.0005). The median RFS was 26.3 months and projected RFS at 3 years of 36.5 months Three prognostic factors were associated with improved RFS in the univariate analysis: preoperative chemotherapy (p = 0.0156), PCI >15 (p = 0.009), Number of chemotherapy agents used for HIPEC (p = 0.005). Conclusion CRS/HIPEC is a safe and effective approach in selected patients with PM of HCC. CRS/HIPEC gives the patient a chance for a good relapse free and overall survival and should be considered as an option.

Published
2018
Full Text
View/download PDF

5. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly: A case-controlled, multicenter study

Author

Alyami, Mohammad, Lundberg, Peter, Kepenekian, Vahan, Goere, Diane, Bereder, Jean-Marc, Msika, Simon, Lorimier, Gérard, Quenet, François, Ferron, Gwenaël, Thibaudeau, Emilie, Abboud, Karine, Lo Dico, Réa, Delroeux, Delphine, Brigand, Cécile, Arvieux, Catherine, Marchal , Frédéric, Tuech, Jean-Jacques, Guilloit, Jean-Marc, Guyon, Frédéric, Peyrat, Patrice, Pezet, Denis, Ortega-Deballon, Pablo, Zinzindohoué, Franck, de Chaisemartin, Cécile, Kianmanesh, Reza, Glehen, Olivier, Passot, Guillaume, Group, BIG-RENAPE, Group, RENAPE, Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Département de chirurgie générale [Gustave Roussy], Institut Gustave Roussy (IGR), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Département de chirurgie, CRLCC Val d'Aurelle - Paul Lamarque, Institut Claudius Regaud, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, CHU Saint-Etienne, Service de Chirurgie d'Oncologie Digestive [CHU Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hôpital de Hautepierre [Strasbourg], CHU Grenoble, Centre de Recherche en Automatique de Nancy (CRAN), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), Service de chirurgie digestive [CHU Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU), Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, Centre Léon Bérard [Lyon], CHU Clermont-Ferrand, Service de Chirurgie Digestive, Cancérologique, Générale, Endocrinienne et Urgences (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de chirurgie digestive, générale et cancérologique [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre Hospitalier Universitaire de Reims (CHU Reims), Ciblage thérapeutique en Oncologie (EA3738), Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon

Subjects
Male, MESH: Combined Modality Therapy, Health Status, 030230 surgery, MESH: Cause of Death, 0302 clinical medicine, MESH: Aged, 80 and over, Cause of Death, Antineoplastic Combined Chemotherapy Protocols, MESH: Peritoneal Neoplasms, Young adult, Peritoneal Neoplasms, MESH: Health Status, Cause of death, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, Age Factors, Cytoreduction Surgical Procedures, Middle Aged, Combined Modality Therapy, MESH: Case-Control Studies, 3. Good health, MESH: Antineoplastic Combined Chemotherapy Protocols, Oncology, Failure to Rescue, Health Care, Cardiovascular Diseases, MESH: Young Adult, 030220 oncology & carcinogenesis, Cohort, Hyperthermic intraperitoneal chemotherapy, Female, Adult, medicine.medical_specialty, Adolescent, MESH: Failure to Rescue, Health Care, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Young Adult, medicine, Humans, MESH: Cytoreduction Surgical Procedures, MESH: Hyperthermia, Induced, Aged, Retrospective Studies, MESH: Adolescent, MESH: Age Factors, MESH: Humans, business.industry, Case-control study, MESH: Cardiovascular Diseases, Retrospective cohort study, MESH: Adult, MESH: Retrospective Studies, Hyperthermia, Induced, MESH: Male, Surgery, Case-Control Studies, Conventional PCI, Peritoneal Cancer Index, business, MESH: Female, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; OBJECTIVE:This study was designed to identify factors associated with morbidity and mortality in patients older than 70 years who underwent cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis (PC).BACKGROUND:Major surgery is associated with higher morbidity and mortality in elderly patients. For PC, CRS and HIPEC is the only current potential curative therapy, but the risks inherent to this patient population have called its benefits into question.METHODS:We retrospectively analyzed a multi-center database from 1989 to 2015. All patients who underwent CRS and HIPEC for PC were selected and patients older than 70 years were matched 1:4 with a younger cohort according to cancer origin, peritoneal cancer index (PCI), and completeness of cytoreduction. Major morbidity and mortality were analyzed.RESULTS:Of 2328 patients, 188 patients older than aged 70 years were matched with 704 younger patients. Patients older than aged 70 years demonstrated a higher American Society of Anesthesiologist score (≥ASA III 10.8 vs. 6.6 %, p = 0.008). There was no difference in overall 90-day morbidity (≥70: 45.7 % vs. 7 (95 % CI 1.051-5.798, p = 0.038) and HIPEC duration (95 % CI 1.106-6.235, p = 0.028) were independent factors associated with morbidity in elderly patients.CONCLUSIONS:CRS and HIPEC appear feasible for selected patients older than aged 70 years, albeit with a higher risk of medical complications associated with increased mortality.

Published
2016
Full Text
View/download PDF

6. Role of Preoperative Optimization of the Liver for Resection in Patients with Hilar Cholangiocarcinoma Type III

Author

Damien Olivié, Stéphane Grandadam, Philippe Compagnon, Yannick Malledant, Alexis Arnaud, Bernard Launois, Bernard Meunier, Karim Boudjema, Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Foie, métabolismes et cancer, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service de radiologie et imagerie médicale [Rennes] = Radiology [Rennes], and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
Male, MESH: Lymphatic Metastasis, 030230 surgery, Gastroenterology, Cholangiocarcinoma, 0302 clinical medicine, Surgical oncology, Clinical endpoint, MESH: Peritoneal Neoplasms, Peritoneal Neoplasms, MESH: Treatment Outcome, Incidence (epidemiology), Hazard ratio, MESH: Neoplasm Staging, MESH: Follow-Up Studies, Jaundice, Survival Rate, Treatment Outcome, Liver, Oncology, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Female, medicine.symptom, MESH: Preoperative Care, medicine.medical_specialty, MESH: Survival Rate, MESH: Bile Duct Neoplasms, Preoperative care, 03 medical and health sciences, Internal medicine, Preoperative Care, medicine, Humans, Neoplasm Invasiveness, Survival rate, Neoplasm Staging, Retrospective Studies, MESH: Humans, business.industry, MESH: Retrospective Studies, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Retrospective cohort study, MESH: Neoplasm Invasiveness, MESH: Cholangiocarcinoma, MESH: Male, MESH: Bile Ducts, Intrahepatic, Bile Ducts, Intrahepatic, Bile Duct Neoplasms, Surgery, business, MESH: Female, MESH: Liver, Follow-Up Studies
Abstract

International audience; BACKGROUND: Long-term survival after complete resection of hilar cholangiocarcinoma remains disappointing. The aim of this retrospective study was to assess the impact of liver optimization on postoperative outcome of hilar cholangiocarcinoma type III. MATERIALS AND METHODS: In a retrospective, single-center analysis, outcomes in patients with hilar cholangiocarcinoma type III who underwent resection after preoperative liver optimization (preoperative transhepatic biliary drainage [PTBD], bile replacement, and/or portal vein embolization [PVE]) were compared with nonoptimized controls. RESULTS: Of 41 patients undergoing surgery, 38 patients undergoing curative intent procedures were identified, of whom 15 underwent preoperative optimization. After PTBD, direct bilirubin decreased from 218.0 ± 184.2 to 75.9 ± 42.7 μmol/L (P = 0.03), and there was a trend toward decreased AST and ALT levels. Overall, 3- and 5-year survival rates were 47.9 ± 9.1 and 41.9 ± 9.8%. The primary endpoint, 5-year survival after surgery, was not significantly different between groups. Preoperative jaundice was identified as an independent prognostic factor for poor outcome (hazard ratio [HR] 2.12, P = 0.02). Four patients (10.5%) without preoperative optimization died of liver failure within the first 30 days postsurgery, preceded in three cases by intra-abdominal abscesses. PTBD was associated with a lower rate of postoperative intra-abdominal abscesses; however this factor was not independently predictive of higher survival. CONCLUSION: Preoperative optimization of the liver in hilar cholangiocarcinoma Type III reduced the incidence of intra-abdominal abscesses, but its impact on postoperative survival remains unclear.

Published
2010
Full Text
View/download PDF

7. A new internet tool to report peritoneal malignancy extent. PeRitOneal MalIgnancy Stage Evaluation (PROMISE) application

Author

François Quenet, Frédéric Marchal, François-Noël Gilly, Laurent Villeneuve, Jean-Marc Guilloit, M. Carretier, S. Carrere, Clarisse Eveno, Julien Fontaine, Faheez Mohamed, Delphine Vaudoyer, S. Isaac, A. Chevallier, A. Dohan, Cécile Brigand, P. Rousset, F. Poizat, Peggy Dartigues, Julio Abba, Frédéric Dumont, Nicolas Pirro, C. Petorin, Frédéric Guyon, G. Lang-Averous, S. Evrard, Gérard Lorimier, Karine Abboud, P. Rat, E. Mery, G. Pourcher, Jack Porcheron, Pablo Ortega-Deballon, M. Messager, Rea Lo Dico, Nicolas Goasguen, Pierre Meeus, R. Tetreau, Houda Ben Rejeb, S. Durand-Fontanier, P. Peyrat, A. Mariani, Dominique Elias, D. Bouzard, D. Geffroy, D. Delroeux, J.M. Bereder, C. de Chaisemartin, Christophe Mariette, R. Kianmanesh, Pierre-Jean Valette, Jean-Jacques Tuech, M. H. Laverrière, B. Lelong, Guillaume Piessen, C. Labbé, Mehdi Karoui, S. Velasco, Guillaume Passot, Diane Goéré, V. Barrau, G. Balague, V. Loi, Olivier Glehen, P. Rousselot, Jean-Marc Regimbeau, Emilie Thibaudeau, Thomas Courvoisier, V. Verriele-Beurrier, Frédéric Bibeau, G. Desolneux, M. Chassang, Marc Pocard, Magali Svrcek, Jérémie H. Lefevre, J. Lacroix, O. Fay, Franck Zinzindohoué, Catherine Arvieux, Naoual Bakrin, Denis Pezet, A. Leroux, Cédric Nadeau, Charles Sabbagh, Romuald Wernert, Bruno Heyd, Pascale Mariani, S. Msika, S. Valmary-Degano, L. Ghouti, A. Thivolet, Clarisse Dromain, R. Kaci, G. Ferron, Pôle Information Médicale Evaluation Recherche (IMER), Hospices Civils de Lyon (HCL), Ciblage thérapeutique en Oncologie (EA3738), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Département de chirurgie, CRLCC Val d'Aurelle - Paul Lamarque, and Département de radiothérapie

Subjects
MESH: Medical Records, medicine.medical_specialty, Scoring application, [SDV.CAN]Life Sciences [q-bio]/Cancer, Medical Records, Peritoneal malignancy, 03 medical and health sciences, Peritoneal Neoplasm, 0302 clinical medicine, MESH: Patient Care Team, Predictive Value of Tests, Medicine, Resectability, MESH: Peritoneal Neoplasms, Humans, Stage (cooking), Peritoneal Neoplasms, Neoplasm Staging, Patient Care Team, Internet, MESH: Humans, business.industry, Medical record, MESH: Peritoneum, Reproducibility of Results, General Medicine, MESH: Neoplasm Staging, Peritoneal cancer index, MESH: Predictive Value of Tests, 3. Good health, Surgery, MESH: Reproducibility of Results, MESH: Internet, Oncology, 030220 oncology & carcinogenesis, Predictive value of tests, Conventional PCI, Peritoneal Cancer Index, 030211 gastroenterology & hepatology, Radiology, Peritoneal diseases, Extent disease, Peritoneum, business, Peritoneal carcinomatosis, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Based on the importance of assessing the true extent of peritoneal disease, PeRitOneal MalIgnancy Stage Evaluation (PROMISE) internet application (www.e-promise.org) has been developed to facilitate tabulation and automatically calculate surgically validated peritoneal cancer index (PCI), and other surgically validated scores as Gilly score, simplified peritoneal cancer index (SPCI), Fagotti and Fagotti-modified scores. This application offers computer-assistance to produce simple, quick but precise and standardized pre, intra and postoperative reports of the extent of peritoneal metastases and may help specialized and non-specialized institutions in their current practice but also facilitate research and multicentre studies on peritoneal surface malignancies.

Published
2016
Full Text
View/download PDF

8. Closed Hyperthermic Intraperitoneal Chemotherapy with Open Abdomen: a Novel Technique to Reduce Exposure of the Surgical Team to Chemotherapy Drugs

Author

Nicolas Cheynel, Pablo Ortega-Deballon, Laurent Benoit, Patrick Rat, Giovanni Di Giacomo, Bruno Chauffert, Service de Chirurgie Digestive, Cancérologique, Générale, Endocrinienne et Urgences (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Département d'oncologie médicale [Centre Georges-François Leclerc], Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, and Ortega Deballon, Pablo

Subjects
Laparoscopic surgery, Operating Rooms, MESH: Combined Modality Therapy, MESH: Body Temperature, [SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/Surgery, medicine.medical_treatment, MESH: Laparoscopy, 030230 surgery, Body Temperature, MESH: Patient Care Team, 0302 clinical medicine, Port (medical), Laparotomy, MESH: Peritoneal Neoplasms, Laparoscopy, Digestive System Surgical Procedures, Peritoneal Neoplasms, MESH: Digestive System Surgical Procedures, medicine.diagnostic_test, Abdominal Cavity, Surgical wound, Combined Modality Therapy, 3. Good health, Occupational Diseases, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Hyperthermic intraperitoneal chemotherapy, Colorectal Neoplasms, MESH: Occupational Diseases, medicine.medical_specialty, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, MESH: Pseudomyxoma Peritonei, Article, 03 medical and health sciences, medicine, Humans, MESH: Hyperthermia, Induced, Patient Care Team, Surgical team, MESH: Humans, business.industry, MESH: Abdominal Cavity, Hyperthermia, Induced, Pseudomyxoma Peritonei, Surgery, body regions, Chemotherapy, Cancer, Regional Perfusion, MESH: Operating Rooms, MESH: Chemotherapy, Cancer, Regional Perfusion, Abdomen, business, MESH: Colorectal Neoplasms
Abstract

International audience; BACKGROUND: Exposure of the surgical team to toxic drugs during hyperthermic intraperitoneal chemotherapy (HIPEC) remains a matter of great concern. During closed-abdomen HIPEC, operating room staff are not exposed to drugs, but the distribution of the heated liquid within the abdomen is not optimal. With open-abdomen HIPEC, the opposite is true. Although the open-abdomen method is potentially more effective, it has not become a standard procedure because of the risk of exposure of members of the team to drugs. METHODS: We present a new technique (closed HIPEC with open abdomen) which ensures protection against potentially contaminating exposure to liquids, vapours and aerosols, and allows permanent access to the whole abdominal cavity. Its principle is to extend the abdominal surgical wound upwards with a sort of "glove-box". The cutaneous edges of the laparotomy are stapled to a latex "wall expander". The expander is draped over a special L-section metal frame placed above the abdomen. A transparent cover containing a "hand-access" port, like those used in laparoscopic surgery, is fixed inside the frame. RESULTS: In 10 patients, this device proved to be hermetic for both liquids and vapours. Intra-abdominal temperature was maintained between 42 and 43 degrees C during most of the procedure. The whole abdominal cavity was accessible to the surgeon, allowing optimal exposure of all peritoneal surfaces. CONCLUSION: This technique allows optimal HIPEC, while limiting the potential toxic effects for the surgical, medical and paramedical teams.

Published
2007
Full Text
View/download PDF

9. High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study

Author

Bruno Chauffert, Olivier Facy, François Ghiringhelli, Patrick Rat, Pablo Ortega-Deballon, Guy Magnin, Sylvain Ladoire, Sophie Al Samman, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), Service de Chirurgie Digestive, Cancérologique, Générale, Endocrinienne et Urgences (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Service d'anesthésie réanimation, Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Centre hospitalier universitaire d'Amiens ( CHU Amiens-Picardie ), CHU Amiens-Picardie, Ortega Deballon, Pablo, Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bourgogne (UB)-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement

Subjects
MESH : Hyperthermia, Induced, MESH: Combined Modality Therapy, Organoplatinum Compounds, [SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/Surgery, Swine, 030230 surgery, MESH : Pressure, 0302 clinical medicine, Medicine, MESH: Peritoneal Neoplasms, MESH: Animals, MESH : Female, [ SDV.MHEP.CHI ] Life Sciences [q-bio]/Human health and pathology/Surgery, MESH: Swine, Peritoneal Neoplasms, MESH: Organoplatinum Compounds, MESH: Peritoneum, Intraperitoneal chemotherapy, Combined Modality Therapy, Peritoneal carcinomatosis, Oxaliplatin, MESH : Antineoplastic Agents, Chemotherapy Drugs, 030220 oncology & carcinogenesis, High pressure, Anesthesia, Female, Hyperthermic intraperitoneal chemotherapy, Peritoneum, Cytoreductive surgery, MESH: Pressure, medicine.drug, Hyperthermia, medicine.medical_specialty, Antineoplastic Agents, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, MESH : Organoplatinum Compounds, 03 medical and health sciences, MESH : Peritoneal Neoplasms, Pressure, Animals, MESH : Peritoneum, MESH: Hyperthermia, Induced, business.industry, Hyperthermia, Induced, MESH : Chemotherapy, Cancer, Regional Perfusion, MESH : Swine, medicine.disease, digestive system diseases, Surgery, Chemotherapy, Cancer, Regional Perfusion, MESH: Antineoplastic Agents, MESH: Chemotherapy, Cancer, Regional Perfusion, MESH : Animals, business, MESH : Combined Modality Therapy, MESH: Female
Abstract

International audience; BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) achieve good results in selected patients with peritoneal carcinomatosis. High intra-abdominal pressure could enhance the penetration of chemotherapy drugs. The aim of this study was to compare the effects of high pressure and hyperthermia when used separately and when combined in terms of blood and tissue absorption of oxaliplatin in a swine model of intraperitoneal chemotherapy. METHODS: Four groups of 5 pigs each underwent laparotomy and open intraperitoneal chemotherapy with oxaliplatin at a constant concentration (150 mg/L) for 30 minutes in normothermia and atmospheric pressure (group 1), or hyperthermia (42°C) and atmospheric pressure (group 2), or normothermia and high pressure (25 cm H2O) (group 3), or hyperthermia and high pressure (group 4). High pressure was achieved thorough a water column over the abdomen. Systemic absorption and abdominal tissue mapping of the penetration of oxaliplatin in each group were studied. RESULTS: Blood concentrations of oxaliplatin were similar in the different groups. Hyperthermia achieved higher concentrations in visceral surfaces (P = 0.0014), but not in parietal surfaces. High pressure enhanced diffusion of the drug in both the visceral and parietal peritoneum (P = 0.0058 and P = 0.0044, respectively). The combination of hyperthermia and high pressure significantly increased the penetration of oxaliplatin and achieved the highest tissue concentrations (10.39 mg/kg vs 5.48 mg/kg; P = 0.00001 in the visceral peritoneum, and 66.16 mg/kg vs 35.62 mg/kg; P = 0.0003 in the parietal peritoneum). CONCLUSIONS: Open high-pressure HIPEC with oxaliplatin is feasible in the pig. Hyperthermia enhances diffusion in the visceral peritoneum, whereas high pressure is effective in the visceral and parietal peritoneum. The combination of the two achieves the highest tissue concentrations of oxaliplatin.

Published
2012
Full Text
View/download PDF

10. Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis

Author

B. Duthey, François Bertucci, David Jérémie Birnbaum, Thérèse Gargi, Danièle Salaün, Ali Badache, Olivier Tredan, Pascal Finetti, Nathalie Bendriss-Vermare, J. Gillibert-Duplantier, Vanja Sisirak, Le myofibroblaste hépatique : différenciation, rôles physiopathologiques, apoptose, Institut National de la Santé et de la Recherche Médicale ( INSERM ), E14, Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), E11, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
MESH: Carcinoma, Cancer Research, Small interfering RNA, MESH : Pleural Neoplasms, MESH: Matrix Metalloproteinases, Receptor, ErbB-2, MESH : Receptors, Cell Surface, MESH : Breast Neoplasms, MESH : RNA, Small Interfering, Receptor tyrosine kinase, Metastasis, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH : Receptor, erbB-2, Cell Movement, MESH: RNA, Small Interfering, MESH: Up-Regulation, MESH: Peritoneal Neoplasms, MESH : Cell Movement, RNA, Small Interfering, skin and connective tissue diseases, MESH: Cell Movement, MESH : Up-Regulation, Peritoneal Neoplasms, MESH: Receptors, Cell Surface, 0303 health sciences, Gene knockdown, biology, MESH : Carcinoma, MESH: Gene Expression Regulation, Neoplastic, Metastatic breast cancer, 3. Good health, Cell biology, Up-Regulation, Gene Expression Regulation, Neoplastic, MESH: Receptor, erbB-2, 030220 oncology & carcinogenesis, MESH: Cell Line, Tumor, MESH : Gene Expression Regulation, Neoplastic, Pleural Neoplasms, Motility, [SDV.CAN]Life Sciences [q-bio]/Cancer, Breast Neoplasms, Receptors, Cell Surface, MESH: Pleural Neoplasms, MESH : Matrix Metalloproteinases, 03 medical and health sciences, MESH: Gene Expression Profiling, Breast cancer, MESH : Peritoneal Neoplasms, Cell Line, Tumor, MESH: Antibodies, Blocking, Genetics, medicine, Humans, Antibodies, Blocking, Molecular Biology, neoplasms, 030304 developmental biology, MESH: Humans, MESH : Antibodies, Blocking, MESH : Cell Line, Tumor, Gene Expression Profiling, MESH : Gene Expression Profiling, Carcinoma, MESH : Humans, medicine.disease, Interleukin-1 Receptor-Like 1 Protein, Matrix Metalloproteinases, Cell culture, biology.protein, MESH: Breast Neoplasms
Abstract

International audience; Overexpression of the ErbB2 receptor tyrosine kinase in breast cancer contributes to tumor development and is associated with poor prognosis. However, the mechanism by which ErbB2 might contribute to metastasis is not well defined. To identify genes that mediate ErbB2-driven cell motility, we performed differential gene expression analysis of ErbB2-expressing migrating breast cancer cells vs mutant ErbB2-expressing non-migrating cells. Among the genes that were specifically induced in migrating cells were known transcriptional targets of ErbB2, such as matrix metalloproteinases, and novel ErbB2 targets. Contribution of selected candidate genes to ErbB2-driven cell motility was tested by small interfering RNA targeting. Knockdown of the soluble form of ST2 (sST2), also called interleukin-1 receptor-like 1, one of the most robustly induced genes, decreased ErbB2-induced cell motility in two different cell lines. In response to ErbB2 activation, sST2 protein expression and secretion were increased. Moreover, recombinant sST2 associated with the plasma membrane and sST2-blocking antibodies reduced ErbB2-induced motility. Interestingly, cells from metastatic breast tumors secreted higher levels of sST2 than primary tumor cells. Finally, sST2 was found at high levels in the serum of metastatic breast cancer patients. Our data suggest that sST2 contributes to breast cancer cell motility and that sST2 secretion is associated with metastasis.

Published
2012
Full Text
View/download PDF

11. Ten-Year Relative Survival and Causes of Death in Elderly Patients Treated With R-CHOP or CHOP in the GELA LNH-985 Trial

Author

Reda Bouabdallah, Hervé Tilly, Bertrand Coiffier, Catherine Thieblemont, Nicolas Mounier, Hervé Ghesquières, Philippe Gaulard, Violaine Safar, Natacha Heutte, Josette Brière, Eric Van Den Neste, Pierre Feugier, Daniela Robu, Gvh et Gvl : Physiopathologie Chez l'Homme et Chez l'Animal, Incidence et Role Therapeutique, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d’études des transformations des activités physiques et sportives (CETAPS), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut de Recherche Interdisciplinaire Homme et Société (IRIHS), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service d'anatomo-pathologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Département Hématologie (FNCLCC), Centre Léon Bérard [Lyon], Cliniques Universitaires Saint-Luc [Bruxelles], Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Laboratoire de Biologie Moléculaire de la Cellule (LBMC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), College of Information and Electrical Engineering [Beijing] (CIEE), China Agricultural University (CAU), Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers (ANTICIPE), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe Régional d'Etudes sur le CANcer (GRECAN), Normandie Université (NU)-Normandie Université (NU)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-IFR146, Service de biochimie [CHU Caen], Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Laboratoire d'informatique de l'École polytechnique [Palaiseau] (LIX), Centre National de la Recherche Scientifique (CNRS)-École polytechnique (X), Centre de Recherche et d'Etude en Droit et Science Politique [Dijon] (CREDESPO), Université de Bourgogne (UB)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Institut de Recherche Interdisciplinaire Homme et Société (IRIHS)

Subjects
Male, Cancer Research, [SDV]Life Sciences [q-bio], CHOP, Antibodies, Monoclonal, Murine-Derived, 0302 clinical medicine, Cause of Death, Antineoplastic Combined Chemotherapy Protocols, MESH: Peritoneal Neoplasms, Glycolysis, MESH: Animals, MESH: Oxygen Consumption, ComputingMilieux_MISCELLANEOUS, Aged, 80 and over, MESH: Energy Metabolism, Hematology, Middle Aged, Warburg effect, 3. Good health, Oncology, Vincristine, MESH: Enzyme Inhibitors, 030220 oncology & carcinogenesis, Female, Lymphoma, Large B-Cell, Diffuse, Rituximab, medicine.medical_specialty, MESH: Mitochondria, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Pleural Neoplasms, 03 medical and health sciences, MESH: Pyruvate Dehydrogenase Complex, medicine, MESH: Mice, Nude, Humans, Secretion, MESH: Tumor Cells, Cultured, Cyclophosphamide, MESH: Mice, MESH: Pyruvates, Aged, Neoplasm Staging, MESH: Humans, MESH: Mesothelioma, business.industry, Metabolism, Surgery, Metabolic pathway, MESH: Cisplatin, Doxorubicin, Anaerobic glycolysis, Cancer cell, Cancer research, Prednisone, business, MESH: Female, Follow-Up Studies, 030215 immunology
Abstract

International audience; Most cancer cells exhibit increased anaerobic glycolysis and use this metabolic pathway for the generation of ATP as a main source of energy. This impaired metabolism of glucose, leading to the secretion of lactic acid even in the presence of oxygen, is named the Warburg effect. Because cancer cells are partly or mainly dependent on such a pathway to generate ATP, inhibition of glycolysis may slow down the proliferation or kill cells.

Published
2012
Full Text
View/download PDF

12. Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study

Author

Le Roux, Catherine, Lombard-Bohas, Catherine, Delmas, Christelle, Dominguez-Tinajero, Sophie, Ruszniewski, Philippe, Samalin, Emmanuelle, Raoul, Jean-Luc, Renard, Pascal, Baudin, Eric, Robaskiewicz, Michel, Mitry, Emmanuel, Cadiot, Guillaume, Renseigné, Non, Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université Lille Nord de France (COMUE)-UNICANCER, Department of Gastroenterology, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CRLC Val d'Aurelle-Paul Lamarque, CRLCC Val d'Aurelle - Paul Lamarque, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), polyclinique de courlancy, Polyclinique de Courlancy, Institut Gustave Roussy (IGR), Médecine nucléaire, Département d'imagerie médicale [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Hôpital Ambroise Paré [AP-HP], Université de Reims Champagne-Ardenne (URCA), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Université de Lille-UNICANCER

Subjects
Male, MESH: Tumor Burden, Multivariate analysis, Time Factors, MESH: Lymphatic Metastasis, MESH: Lymph Nodes, Kaplan-Meier Estimate, 030230 surgery, 0302 clinical medicine, MESH: Aged, 80 and over, Risk Factors, MESH: Liver Neoplasms, MESH: Risk Factors, MESH: Emergencies, Odds Ratio, MESH: Peritoneal Neoplasms, Mesentery, Peritoneal Neoplasms, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, Liver Neoplasms, Gastroenterology, MESH: Follow-Up Studies, Middle Aged, MESH: Ileal Neoplasms, 3. Good health, Tumor Burden, Neuroendocrine Tumors, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Curative surgery, Female, France, Adult, Multiple tumours, medicine.medical_specialty, MESH: Neuroendocrine Tumors, Time to relapse, [SDV.CAN]Life Sciences [q-bio]/Cancer, Disease-Free Survival, MESH: Multivariate Analysis, 03 medical and health sciences, Emergency surgery, medicine, Humans, MESH: Mesentery, MESH: Kaplan-Meier Estimate, Aged, Retrospective Studies, MESH: Humans, Hepatology, business.industry, MESH: Time Factors, MESH: Adult, MESH: Retrospective Studies, Confidence interval, MESH: Male, MESH: Odds Ratio, Surgery, Ileal Neoplasms, MESH: France, Multivariate Analysis, MESH: Disease-Free Survival, Lymph Nodes, Emergencies, business, MESH: Female, Follow-Up Studies
Abstract

International audience; AIM: To evaluate the characteristics of postoperative relapse, predictive factors and time to relapse after curative surgery for well-differentiated neuroendocrine tumours of the ileum, without hepatic or other distant metastases. METHODS: Clinical data of patients entered into the Groupe d'étude des Tumeurs Endocrines database were collected and analysed retrospectively to identify factors predictive of relapse. RESULTS: Among 100 patients followed for a median of 56.5 (range 1-290) months, 42 relapsed after a median follow-up of 57.5 (range 6-176) months, with liver lesions in 27 (64.3%). Median disease-free survival (Kaplan-Meier) was 88 months (95% confidence interval 72-115). Disease-free survival was shorter for emergency surgery patients (p20mm (p=0.02), and those with multiple tumours (p=0.07). Multivariate analysis retained emergency surgery (odds-ratio 4.04 [95% confidence interval 2.01-8.11]), distant mesenteric lymph-node metastases (odds-ratio 2.53 [95% confidence interval 1.22-5.25]), and multiple tumours (odds-ratio 2.14 [95% confidence interval 1.01-4.50]), as being significantly associated with relapse. CONCLUSION: Patients who underwent emergency surgery, with distant mesenteric lymph-node metastases or with multiple ileal tumours relapsed earlier. Closer monitoring for the patients with these risk factors may be required.

Published
2011
Full Text
View/download PDF

13. Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murine model of peritoneal carcinomatosis

Author

Patrick Rat, Hervé Tixier, François Radais, Delphine Delroeux, François Ghiringhelli, Sylvain Ladoire, Olivier Facy, Pablo Ortega-Deballon, Bruno Chauffert, Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Service de Chirurgie Digestive, Cancérologique, Générale, Endocrinienne et Urgences (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Chirurgie Digestive [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), This paper was supported by grants from the French National League against Cancer (Committees of Saône et Loire, Nièvre, and Côte d'Or)., BMC, Ed., Service de chirurgie digestive et cancérologie, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), Service de chirurgie digestive [Besançon], Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz, Service d'oncologie médicale, and CHU Amiens-Picardie

Subjects
MESH : Hyperthermia, Induced, MESH : Rats, Inbred Strains, Cancer Research, Pathology, Pharmacology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Peritoneal Neoplasm, 0302 clinical medicine, MESH : Tumor Cells, Cultured, Tumor Cells, Cultured, Medicine, MESH: Peritoneal Neoplasms, MESH : Female, MESH: Animals, Peritoneal Neoplasms, Ovarian Neoplasms, MESH : Cell Survival, 0303 health sciences, MESH : Rats, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, MESH: Rats, Inbred Strains, 3. Good health, MESH : Antineoplastic Agents, MESH: Ovarian Neoplasms, Epinephrine, Oncology, MESH: Cell Survival, 030220 oncology & carcinogenesis, Female, medicine.drug, Hyperthermia, medicine.medical_specialty, MESH: Rats, Cell Survival, MESH: Epinephrine, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, lcsh:RC254-282, MESH : Cisplatin, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH : Peritoneal Neoplasms, In vivo, Animals, Humans, MESH: Tumor Cells, Cultured, MESH: Hyperthermia, Induced, 030304 developmental biology, Cisplatin, MESH: Humans, MESH : Ovarian Neoplasms, business.industry, Research, MESH : Humans, Rats, Inbred Strains, Hyperthermia, Induced, medicine.disease, MESH : Disease Models, Animal, Rats, Disease Models, Animal, MESH: Cisplatin, Apoptosis, MESH : Epinephrine, Cancer cell, MESH: Antineoplastic Agents, MESH : Animals, MESH: Disease Models, Animal, business, Ovarian cancer, MESH: Female
Abstract

Background The best method to deliver intraperitoneal chemotherapy (IPC) for peritoneal carcinomatosis from ovarian cancer is not well defined. The aim of this study was to assess the ability of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a rat model of peritoneal carcinomatosis. Methods Four groups of 5 BDIX rats with ovarian peritoneal carcinomatosis underwent IPC with 30 mg/l of cisplatin according to the following conditions: normothermia at 37° for 1 or 2 hours, hyperthermia at 42°C for 1 hour or normothermia at 37°C for 2 hours with 2 mg/l adrenaline. Tissue platinum content was measured by atomic absorption spectroscopy. The effect of hyperthermia, adrenaline and the duration of exposure to the drug was measured in vivo (tissue concentration of platinum in tumor, abdominal and extra abdominal tissues) and in vitro (cytotoxicity on human ovarian cancer cells). Results In vitro, hyperthermia and longer exposure enhanced the accumulation and the cytotoxic effect of cisplatin on cancer cells. In vivo, only the 2 hours treatment with adrenaline resulted in increased platinum concentrations. The rats treated with adrenaline showed significantly lower concentrations of cisplatin in extra peritoneal tissues than those treated with hyperthermia. Conclusion Adrenaline is more effective than hyperthermia in order to enhance the intratumoral concentration of cisplatin in rats with peritoneal carcinomatosis from ovarian origin. It may also decrease the systemic absorption of the drug.

Published
2011
Full Text
View/download PDF

14. Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies

Author

André Pèlegrin, Isabelle Navarro-Teulon, Jean-Pierre Pouget, Muriel Busson, Pierre-Emmanuel Colombo, François Quenet, Véronique Garambois, Vincent Boudousq, Pierre-Olivier Kotzki, Manuel Bardiès, Stéphanie Ricaud, Samir Boutaleb, Caroline Bascoul-Mollevi, Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de Médecine Nucléaire [Nîmes], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), CRLC Val d'Aurelle-Paul Lamarque, CRLCC Val d'Aurelle - Paul Lamarque, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Institut National du Cancer, grant R09080FF / RPT09005FFA., Le Ster, Yves, and CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1)

Subjects
Pathology, Time Factors, medicine.medical_treatment, MESH: Antibodies, Monoclonal, Iodine Radioisotopes, Peritoneal Neoplasm, Mice, 0302 clinical medicine, Medicine, MESH: Peritoneal Neoplasms, MESH: Animals, Saline, Peritoneal Cavity, Peritoneal Neoplasms, 0303 health sciences, peritoneal carcinomatosis, Antibodies, Monoclonal, MESH: Peritoneal Cavity, MESH: Iodine Radioisotopes, 3. Good health, MESH: Staining and Labeling, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Radioimmunotherapy, MESH: Survival Analysis, Toxicity, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Auger electrons, MESH: Tomography, X-Ray Computed, medicine.medical_specialty, Biodistribution, MESH: Cell Line, Tumor, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH: Biological Transport, MESH: Radioimmunotherapy, Intraperitoneal injection, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, MESH: Tomography, Emission-Computed, Single-Photon, [SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine, 03 medical and health sciences, Peritoneal cavity, [SDV.CAN] Life Sciences [q-bio]/Cancer, Cell Line, Tumor, Bioluminescence imaging, Animals, Radiology, Nuclear Medicine and imaging, Radiometry, MESH: Mice, 030304 developmental biology, Tomography, Emission-Computed, Single-Photon, Staining and Labeling, business.industry, MESH: Time Factors, MESH: Radiometry, Biological Transport, Survival Analysis, business, Nuclear medicine, Tomography, X-Ray Computed, MESH: Female
Abstract

We assessed the efficiency and toxicity of brief intraperitoneal radioimmunotherapy using high activities of 125I-labeled monoclonal antibody (mAb) in the treatment of small-volume peritoneal carcinomatosis. Methods: Brief intraperitoneal radioimmunotherapy consisted of a 185-MBq (740 MBq/mg) intraperitoneal injection of 125I-35A7 (an anti–carcinoembryonic antigen mAb) into athymic nude mice 4 d after peritoneal tumor xenografting and, after 1 h, abundant washing of the peritoneal cavity with saline solution to remove unbound radioactivity. Another group of mice received this treatment plus a 37-MBq intravenous injection of 125I-35A7 on day 7 or 11 after grafting. Control groups received a brief treatment followed by an additional intravenous injection on day 7 of either saline solution or irrelevant 125I-PX. Tumor growth was monitored by bioluminescence imaging and SPECT/CT, and hematologic toxicity was evaluated by complete blood counts. Survival time was reported, and the mice were sacrificed when the bioluminescence signal reached 4.5 × 107 photons/s. The biodistribution of 125I-35A7 mAb after intravenous or brief treatment was assessed, and the mean absorbed irradiation dose by organs and tumors was calculated using the MIRD formalism. Results: Mild, transient hematologic toxicity was observed after the brief treatment plus intravenous 125I-mAb, with no weight loss. Median survival increased from 32 d in the control groups, to 46 d in the brief treatment group, to 66 d in the group additionally receiving intravenous treatment on day 11, to 73 d in the group additionally receiving intravenous treatment on day 7. The brief treatment alone resulted in a 3-fold higher tumor-to-blood uptake ratio than did the standard intravenous treatment, and the mean absorbed irradiation doses by tumors were 11.6 Gy for the brief treatment and 16.7 Gy for the additional intravenous treatment. For healthy tissues other than blood, the mean absorbed irradiation dose did not exceed 1 Gy after brief treatment and 4.2 Gy after intravenous treatment. Conclusion: The efficiency, low toxicity, and high tumor–to–healthy tissue uptake ratio associated with brief intraperitoneal 125I-35A7 radioimmunotherapy suggest that this method can be used in combination with radiation-synergistic drugs in the therapy of small-volume peritoneal carcinomatosis after cytoreductive surgery.

Published
2010
Full Text
View/download PDF

15. Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer

Author

Delphine Delroeux, Emmanuel Guardiola, Xavier Pivot, Veronique Lorgis, Ulrich Stein, Bernard Royer, Bruno Chauffert, Marielle Combe, Bruno Heyd, Martin Demarchi, Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de chirurgie viscérale et digestive - Unité de transplantation hépatique, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service d'anesthésie - réanimation, Laboratoire de Pharmacologie Clinique et Toxicologie [CHRU Besancon], Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, and Saas, Philippe

Subjects
Oncology, medicine.medical_treatment, MESH: Intraoperative Care, Carboplatin, chemistry.chemical_compound, Peritoneal Neoplasm, 0302 clinical medicine, Technical Innovations, Surgical oncology, MESH: Carboplatin, Antineoplastic Combined Chemotherapy Protocols, MESH: Peritoneal Neoplasms, 030212 general & internal medicine, Peritoneal Neoplasms, MESH: Treatment Outcome, Ovarian Neoplasms, MESH: Aged, MESH: Middle Aged, MESH: Neoplasm Staging, Middle Aged, Debulking, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, MESH: Cystadenocarcinoma, Serous, 3. Good health, MESH: Ovarian Neoplasms, MESH: Antineoplastic Combined Chemotherapy Protocols, Treatment Outcome, 030220 oncology & carcinogenesis, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Carcinoma, Endometrioid, MESH: Neoplasm Recurrence, Local, Injections, Intraperitoneal, MESH: Injections, Intraperitoneal, medicine.drug, Adult, medicine.medical_specialty, Paclitaxel, [SDV.IMM] Life Sciences [q-bio]/Immunology, lcsh:Surgery, lcsh:RC254-282, MESH: Prognosis, 03 medical and health sciences, Internal medicine, medicine, Humans, MESH: Paclitaxel, Aged, Neoplasm Staging, Cisplatin, Chemotherapy, Intraoperative Care, MESH: Humans, business.industry, Cancer, MESH: Adult, lcsh:RD1-811, medicine.disease, Surgery, Cystadenocarcinoma, Serous, chemistry, MESH: Carcinoma, Endometrioid, MESH: Cisplatin, Chemotherapy, Cancer, Regional Perfusion, Feasibility Studies, MESH: Chemotherapy, Cancer, Regional Perfusion, Neoplasm Recurrence, Local, business, Ovarian cancer, MESH: Feasibility Studies, MESH: Female
Abstract

Background Intra-peritoneal (i.p.) chemotherapy is an encouraging treatment option for ovarian cancer with peritoneum involvement in addition with intravenous (i.v.) chemotherapy. Intra-operative i.p. chemotherapy is an interesting method of administration by enhancing the diffusion of chemotherapy. This study had assessed the feasibility of intra-operative i.p. chemotherapy in patients with peritoneal carcinoma of ovarian cancer. Methods From January 2003 to February 2006, 47 patients with stage III ovarian cancer were treated with standard paclitaxel carboplatin intravenous chemotherapy and debulking surgery with intra-operative i.p. chemotherapy. After optimal cytoreductive surgery, defined by no unresectable residual disease > 1 cm, i.p. chemotherapy was performed during surgery. The peritoneal cavity was filled by 3 litres of isotonic saline pre-heated at 37 degrees and 90 mg of cisplatin. The sequence was repeated twice during 2 hours based on previous published studies which optimized the cisplatin dosage and exposure duration. Optimal diffusion was obtained by stirring by hands during the 2 hours. Results Median age was 59.6 years. No severe haematological or non-haematological toxicity induced by intra operative i.p. chemotherapy was reported. No patient died due to the complications of surgery or the i.p. chemotherapy. No neurotoxicity occurred, and one patients had renal impairment. Conclusion This study demonstrates the feasibility of intra-operative i.p. chemotherapy with cisplatin after optimal resection of peritoneal tumor nodules. Further randomized trials are planned to investigate the clinical benefit of this therapeutic modality.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results